These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 27349252)

  • 21. Rescue hCG to treat empty follicle syndrome after the use of a GnRH agonist as oocyte maturation trigger: First report on fresh embryo transfer and clinical pregnancy.
    Christopoulos G; Vlismas A; Barsoum-Derias E; El-Shawarby S; Trew G; Lavery S
    Hum Fertil (Camb); 2015; 18(4):248-52. PubMed ID: 26400626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.
    Thomsen L; Humaidan P
    Curr Opin Obstet Gynecol; 2015 Jun; 27(3):210-4. PubMed ID: 25811256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P; Papanikolaou EG; Tarlatzis BC
    Hum Reprod; 2009 Oct; 24(10):2389-94. PubMed ID: 19608565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
    Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
    Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
    Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol.
    Chen X; Chen SL; He YX; Ye DS
    J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):133-136. PubMed ID: 23392722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
    Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
    J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles.
    Huang CY; Shieh ML; Li HY
    J Chin Med Assoc; 2016 Jul; 79(7):387-93. PubMed ID: 27147462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
    Abbara A; Islam R; Clarke SA; Jeffers L; Christopoulos G; Comninos AN; Salim R; Lavery SA; Vuong TNL; Humaidan P; Kelsey TW; Trew GH; Dhillo WS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):920-927. PubMed ID: 29446481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.
    O'Neill KE; Senapati S; Dokras A
    Fertil Steril; 2015 Jan; 103(1):264-9. PubMed ID: 25450300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian hyperstimulation syndrome following GnRH agonist trigger-think ectopic.
    Orvieto R; Vanni VS
    J Assist Reprod Genet; 2017 Sep; 34(9):1161-1165. PubMed ID: 28600619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.